COST-EFFECTIVENESS OF TREMELIMUMAB PLUS DURVALUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE UNITED STATES

被引：0
|
作者：
Xiong, X. [1 ]
Guo, J. J. [2 ]
机构：
[1] Univ Cincinnati, Cincinnati, OH USA
[2] Univ Cincinnati, Plain City, OH USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE520
引用
收藏
页码：S152 / S152
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma
    Meng, Rui
    Zhang, Xueke
    Zhou, Ting
    Luo, Mengjie
    Qiu, Yijin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (07) : 1079 - 1086
  • [22] ASSESSING THE COST-EFFECTIVENESS OF LENVATINIB AS A FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN CANADA
    Kim, John J.
    McFarlane, Thomas
    Tully, Stephen
    Wong, William W. L.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E3 - E4
  • [23] Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
    Tamaki, Nobuharu
    Mori, Nami
    Takaki, Shintaro
    Tsuji, Keiji
    Tada, Toshifumi
    Nakamura, Shinichiro
    Ochi, Hironori
    Mashiba, Toshie
    Doisaki, Masao
    Marusawa, Hiroyuki
    Kobashi, Haruhiko
    Fujii, Hideki
    Ogawa, Chikara
    Nonogi, Michiko
    Arai, Hirotaka
    Uchida, Yasushi
    Urawa, Naohito
    Narita, Ryoichi
    Akahane, Takehiro
    Kondo, Masahiko
    Yasui, Yutaka
    Tsuchiya, Kaoru
    Izumi, Namiki
    Kurosaki, Masayuki
    ANTICANCER RESEARCH, 2024, 44 (09) : 3913 - 3918
  • [24] Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma
    de Castria, Tiago Biachi
    Khalil, Danny N.
    Harding, James J.
    O'Reilly, Eileen M.
    Abou-Alfa, Ghassan K.
    FUTURE ONCOLOGY, 2022, 18 (33) : 3769 - 3782
  • [25] Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    He, Xiaofeng
    Tang, Ruilei
    Du, Zedong
    Zhou, Jing
    Zhang, Jian
    Li, Qiu
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (07) : 853 - 859
  • [26] First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States
    Liu, Wenjie
    Huo, Gengwei
    Chen, Peng
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [27] COST EFFECTIVENESS ANALYSIS OF LENVATINIB FOR THE FIRST-LINE TREATMENT OF INDIVIDUALS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
    Li, X.
    Wudong, G.
    Wang, Y.
    VALUE IN HEALTH, 2020, 23 : S37 - S37
  • [28] Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer
    Ye, Zhuo-miao
    Xu, Zhe
    Li, Huan
    Li, Qian
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [29] Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (02) : 87 - 93
  • [30] Cost-effectiveness of nivolumab plus gemcitabine-cisplatin as first-line treatment for advanced urothelial carcinoma in China and the United States
    Xiang, Guiyuan
    Huang, Yueyue
    Gan, Lanlan
    Wang, Linning
    Ding, Yunqi
    Wu, Yuanlin
    Xing, Haiyan
    Liu, Yao
    FRONTIERS IN IMMUNOLOGY, 2024, 15
12345